Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy.

abstract：:The V617F mutation of the JAK2 tyrosine kinase is found in a majority of patients with myeloproliferative disorders. Flow cytometry assays for quantitation of phosphorylated and total protein for JAK2, STAT5, and heat shock proteins (HSPs) were developed to facilitate the study of the JAK/STAT pathway. A cell line hom...

journal_title：Leukemia & lymphoma

authors： Bareng J,Jilani I,Gorre M,Kantarjian H,Giles F,Hannah A,Albitar M

更新日期：2007-11-01 00:00:00

abstract：:In acute myeloid leukemia (AML), cytogenetics predicts treatment outcome for the favorable and poor subgroups but not for the intermediate subgroup. Polymorphisms within the nucleotide excision repair (NER) pathway may lead to interindividual differences in DNA repair capacity, influencing outcome. We studied the role...

journal_title：Leukemia & lymphoma

authors： Strom SS,Estey E,Outschoorn UM,Garcia-Manero G

更新日期：2010-04-01 00:00:00

abstract：:We describe a case of a patient with CD34+, TdT+, CD13-, CD33-, MPO- undifferentiated acute leukemia who refused chemotherapy and who achieved complete hematological remission 14 months after the diagnosis, during a short course of granulocyte-colony stimulating factor (G-CSF) for neutropenia and life threatening infe...

journal_title：Leukemia & lymphoma

authors： Xavier L,Cunha M,Gonçalves C,Teixeira Mdos A,Coutinho J,Ribeiro AC,Lima M

更新日期：2003-12-01 00:00:00

abstract：:In the HOVON68 CLL trial, patients 65 to 75 years of age had no survival benefit from the addition of low-dose alemtuzumab to fludarabine and cyclophosphamide (FC) in contrast to younger patients. The reasons are explored in this 5-year trial update using both survival analysis and competing risk analysis on non-CLL-r...

journal_title：Leukemia & lymphoma

authors： Vojdeman FJ,Van't Veer MB,Tjønnfjord GE,Itälä-Remes M,Kimby E,Polliack A,Wu KL,Doorduijn JK,Alemayehu WG,Wittebol S,Kozak T,Walewski J,Abrahamse-Testroote MC,van Oers MH,Geisler CH

更新日期：2017-03-01 00:00:00

abstract：:Acute graft versus host disease (aGVHD) was first described by Barnes et al. in 1962, who reported a 'secondary disease' in mice after irradiation and infusion of allogeneic spleen cells. The disease manifested as fatal diarrhea and skin abnormalities. They postulated that aGVHD resulted from introducing immunological...

journal_title：Leukemia & lymphoma

authors： Gergis U,van Besien K

更新日期：2019-09-01 00:00:00

abstract：:Ninety-nine patients with "standard risk" Stage IA-IIA Hodgkin's disease observed between January 1983 and December 1990, received radiotherapy only. The complete response rate was 98% (97/99). Twenty-one patients (21%) relapsed, 17 of whom (81%) obtained a second complete remission. The projected 9-year overall survi...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Barbieri E,Gherlinzoni F,Frezza G,Mazza P,Pica A,Ammendolia I,Bendandi M,Neri S,Miniaci G

更新日期：1994-04-01 00:00:00

abstract：:We investigated 41 diffuse large B-cell lymphomas (DLBCL) diagnosed at one center harboring ≥50% of latently Epstein-Barr virus (EBV)-infected neoplastic cells occurring in 34 patients aged ≥50 years and in 7 patients younger than 50 years in the absence of any known immunodeficiency for the expression patterns of EBV...

journal_title：Leukemia & lymphoma

authors： Jöhrens K,Trappe RU,Lenze D,Pfreundschuh M,Ziepert M,Hummel M,Anagnostopoulos I

更新日期：2016-12-01 00:00:00

abstract：:Rituximab is widely used for CD20+ non-Hodgkin lymphoma (NHL). The use of rituximab has been uncommonly associated with pulmonary toxicity. We report here a single institution experience on the clinical characteristics, diagnosis, treatment and outcome of rituximab-induced interstitial lung disease. From May 2007 to F...

journal_title：Leukemia & lymphoma

authors： Liu X,Hong XN,Gu YJ,Wang BY,Luo ZG,Cao J

更新日期：2008-09-01 00:00:00

abstract：:We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (RT) after a metabolic complete response to immunochemotherapy. With a ...

journal_title：Leukemia & lymphoma

authors： Augustyn A,Medeiros LJ,Ludmir EB,Gunther J,Fang P,Li S,Ok CY,Bankston ME,Verma V,Pasalic D,Ahmed S,Nastoupil LJ,Westin JR,Strati P,Neelapu SS,Nair R,Steiner RE,Iyer SP,Rodriguez A,Fayad LE,Flowers CR,Dabaja BS,

更新日期：2021-01-22 00:00:00

abstract：:Primary myelosarcomas, also called leukemia cutis, granulocytic sarcomas or chloromas, are rare extramedullary manifestations of acute myeloid leukemia (AML) which precede bone marrow involvement. Skin infiltration was the most frequent localization associated with a myelomonocytic differentiation. Although first remi...

journal_title：Leukemia & lymphoma

authors： Reinhardt D,Creutzig U

更新日期：2002-03-01 00:00:00

abstract：:Among 318 cases of non-Hodgkin's lymphoma (NHL) treated in our unit, 145 (45.6%) had primary extranodal NHL (PE-NHL). The stomach was the most common site (42.1%), followed by the PE-NHL of the head and neck region. Histologically aggressive histologies (65.5% intermediate and 20.7% high grade) predominated. 89.6% of ...

journal_title：Leukemia & lymphoma

authors： Economopoulos T,Asprou N,Stathakis N,Papageorgiou E,Dervenoulas J,Xanthaki K,Raptis S

更新日期：1996-03-01 00:00:00

abstract：:Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates o...

journal_title：Leukemia & lymphoma

authors： Cummins KD,Gill S

更新日期：2018-07-01 00:00:00

abstract：:Hepatocyte growth factor (HGF) was identified, purified and molecularly cloned as a potent mitogen for mature rat hepatocytes in primary culture. It is one of the largest cytokines and is composed of disulfide-linked subunits of approximately 60 (heavy chain) and 35 kilodaltons (light chain). Recent observations revea...

journal_title：Leukemia & lymphoma

authors： Gohda E,Nakamura S,Yamamoto I,Minowada J

更新日期：1995-10-01 00:00:00

abstract：:Bortezomib and gemcitabine have each shown activity as single agents in mantle cell lymphoma (MCL), which is incurable. The purpose of this phase II study was to determine the efficacy and safety of the previously unstudied combination of bortezomib and gemcitabine in patients with relapsed or refractory MCL. Patients...

journal_title：Leukemia & lymphoma

authors： Kouroukis CT,Fernandez LA,Crump M,Gascoyne RD,Chua NS,Buckstein R,Turner R,Assouline S,Klasa RJ,Walsh W,Powers J,Eisenhauer E

更新日期：2011-03-01 00:00:00

abstract：:We conducted a population-based study to assess how positron emission tomography (PET) is currently used in patients with Hodgkin lymphoma (HL). Four cancer registries from northern Italy were used to identify patients with HL diagnosed from 2006 to 2008. Computed tomography (CT) and PET scans were collected before tr...

journal_title：Leukemia & lymphoma

authors： Luminari S,Cesaretti M,Tomasello C,Guida A,Bagni B,Merli F,Postiglione R,Mangone L,Versari A,Re F,De Lisi V,Ruffini L,Ferretti S,Cuneo A,Federico M

更新日期：2011-09-01 00:00:00

abstract：:Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at a fixed daily dose of 420 mg. Data from real-world studies indicate up to 17.5% of patients discontinue ibrutinib due to toxicity. Hypothetically, j...

journal_title：Leukemia & lymphoma

authors： Akhtar OS,Attwood K,Lund I,Hare R,Hernandez-Ilizaliturri FJ,Torka P

更新日期：2019-07-01 00:00:00

abstract：:To understand the relationship between bcl-2 protein expression and the cell cycle during the processes of differentiation, we examined bcl-2 protein levels expressed during cell cycle phases in differentiating HL-60 human leukemia cells by using a two-color flow cytometric method. In exponentially proliferating HL-60...

journal_title：Leukemia & lymphoma

authors： Kumakura S,Ishikura H,Tsumura H,Nakashima A,Sato Y,Kobayashi S

更新日期：2000-01-01 00:00:00

abstract：:The clinical features at time of diagnosis of long-term survivors with lymphoma type of adult T-cell leukemia (ATL) were compared with those of short-term survivors. We had 51 Japanese patients with lymphoma type of ATL from 1981 to 1989 who had human T-cell leukemia virus type I (HTLV-I) antibody and monoclonal integ...

journal_title：Leukemia & lymphoma

authors： Shimamot Y,Suga K,Igarashi H,Nishimura J,Nawata H,Yamaguchi M

更新日期：1990-01-01 00:00:00

abstract：:We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 month...

journal_title：Leukemia & lymphoma

authors： Chong EA,Svoboda J,Cherian S,Andreadis C,Downs LH,Zhuang H,Alavi A,Tsai DE,Schuster SJ

更新日期：2005-09-01 00:00:00

abstract：:To assess the efficacy of haploidentical hematopoietic stem cell transplantation (HSCT) in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), we retrospectively analyzed 30 cases that presented at our institution. At the time of HSCT, 20 patients (66.7%) had achieved a resp...

journal_title：Leukemia & lymphoma

authors： Li Z,Wang Y,Wang J,Zhang J,Wang Z

更新日期：2018-01-01 00:00:00

abstract：:Contemporary intensive therapies are effective for the majority of pediatric T-lineage acute lymphoblastic leukemia (ALL) patients, thus current challenge is to identify patients who may benefit from alternative treatment modalities. Previously, we demonstrated that human leukemic cell growth in the severe combined im...

journal_title：Leukemia & lymphoma

authors： Uckun FM,Waurzyniak BJ,Sather HN,Sensel MG,Chelstrom L,Nachman J,Gaynon PS,Bostrom B,Ek O,Sarquis M,Steinherz PG,Reaman GH

更新日期：1999-02-01 00:00:00

abstract：:Primary central nervous system lymphoma (PCNSL) is an aggressive neoplasm with a poor prognosis. Early studies of whole brain radiation therapy (WBRT) alone revealed a robust initial response but high rates of local recurrence with long-term follow-up. The addition of high-dose methotrexate (HDMTX)-based chemotherapy ...

journal_title：Leukemia & lymphoma

authors： Milgrom SA,Yahalom J

更新日期：2015-05-01 00:00:00

abstract：:Granulocytic sarcomas (GS) are rare extra medullary tumors composed of myeloid progenitor cells. Bones, lymph nodes and skin are favored sites of involvement. Primary involvement of the ovary is exceedingly rare leading to under diagnosis of GS. We report on a 19-year-old woman who presented with an ovarian mass witho...

journal_title：Leukemia & lymphoma

authors： Mehta J,Kane S

更新日期：2004-04-01 00:00:00

abstract：:One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years. The patient pop...

journal_title：Leukemia & lymphoma

authors： Mi Y,Xue Y,Yu W,Liu S,Zhao Y,Meng Q,Bian S,Wang J

更新日期：2008-03-01 00:00:00

abstract：:Loss of function of the ataxia-telangiectasia mutated (ATM) gene, located on human chromosome 11q22-23, is the cause of ataxia-telangiectasia (A-T), which is associated with an extremely high risk for lymphoma. Abnormalities in 11q22-23, including deletions and mutations of the ATM gene, have been reported in T-cell p...

journal_title：Leukemia & lymphoma

authors： Lossos IS,Thorstenson YR,Wayne TL,Oefner PJ,Levy R,Chu G

更新日期：2002-05-01 00:00:00

abstract：:Current chemoimmunotherapy is unable to cure up to 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL). Targeting the mechanisms by which DLBCL evades apoptosis is crucial to overcoming treatment failure in this heterogeneous disease as both current and novel treatments depend on the apoptosis of mali...

journal_title：Leukemia & lymphoma

authors： Gifford G,Stevenson W,Best G

更新日期：2020-12-01 00:00:00

abstract：:We retrospectively examined the results of a new chemo-free approach combining blinatumomab with ponatinib (blina/pona) in 26 relapsed/refractory Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patients. All but one achieved complete morphologic remission, and 23 achieved a complete molecular response. ...

journal_title：Leukemia & lymphoma

authors： Couturier MA,Thomas X,Raffoux E,Huguet F,Berthon C,Simand C,Gallego-Hernanz MP,Hicheri Y,Hunault Berger M,Saillard C,Leguay T,Loiseau C,Béné MC,Chevallier P

更新日期：2020-11-06 00:00:00

abstract：:This retrospectively collected laboratory-based surveillance data includes 575 healthcare-associated bloodstream infections (BSIs) in 350 patients with hematological malignancy in Tampere University Hospital, Finland, during 1999-2001 and 2005-2010. The most common underlying diseases were acute myelogenous leukemia (...

journal_title：Leukemia & lymphoma

authors： Åttman E,Aittoniemi J,Sinisalo M,Vuento R,Lyytikäinen O,Kärki T,Syrjänen J,Huttunen R

更新日期：2015-01-01 00:00:00

abstract：:Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interac...

journal_title：Leukemia & lymphoma

authors： Pleyer C,Wiestner A,Sun C

更新日期：2018-12-01 00:00:00

abstract：:We describe here a rare case of malignant lymphoma followed by plasmacytoma in Hashimoto's thyroiditis. The patient developed malignant lymphoma (small, non-cleaved cell, and non Burkitt's type by Working Formulation classification), and remained in remission for 2 years after receiving combination chemotherapy, and t...

journal_title：Leukemia & lymphoma

authors： Hasegawa Y,Itoh T,Tamagawa Y,Komeno T,Kojima H,Ninomiya H,Yatabe Y,Mori N,Nagasawa T

更新日期：1999-11-01 00:00:00